Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer

V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) mutated lung cancer is relatively aggressive and is resistant to currently available therapies. In a recent phase II study for patients with BRAF-V600E non-small cell lung cancer (NSCLC), BRAF V600E inhibitor demonstrated evidence of activity, but...

Descripción completa

Detalles Bibliográficos
Autores principales: Joshi, Monika, Rice, Shawn J., Liu, Xin, Miller, Bruce, Belani, Chandra P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338247/
https://www.ncbi.nlm.nih.gov/pubmed/25706985
http://dx.doi.org/10.1371/journal.pone.0118210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338247/
https://www.ncbi.nlm.nih.gov/pubmed/25706985
http://dx.doi.org/10.1371/journal.pone.0118210

Ejemplares similares